France Pharmaceutical Market Overview – Austerity measures will impact pharmaceutical market growth

Introduction

The prescription pharma market in France was valued at $38.8bn in sales in 2009, having by 3.1% (CAGR; 2005–09). Key growth drivers include growing use of chronic high-value innovative treatments driven by an aging population, high public healthcare expenditure as proportion of total healthcare expenditure, physician preference for prescribing branded drugs as well as high patient brand loyalty.
Features and benefits

* Overview of socioeconomic and demographic trends, healthcare system, regulation, pricing and reimbursement and intellectual property in France
* Assesses the size of the French pharmaceutical market by prescribing setting, therapy area, leading brands and by leading companies
* Examines the French generics and biosimilars landscape in terms of regulatory issues, level of penetration, key players and degree of brand erosion
* Quantifies the R&D and manufacturing infrastructure for the leading pharmaceutical companies, including key metrics and domestic M&A analysis
Highlights

Despite having a higher birth rate than most European countries, with its ageing population France is encountering difficulties in handling its health account deficit, a situation made worse by the economic downturn. Hence France has turned towards social system reforms and austerity measures.Despite having a favourable market for innovative and expensive drugs a range of cost-cutting measures such as pricing and reimbursement cuts will have a negative impact on the French pharmaceutical market.Once considered the immature generics market, France has considerably increased its generics uptake although there is still a significant scope for improvement. Physicians’ resistance to generics use remains the greatest obstacle with adequate physicians’ financial incentives necessary in the future.
Your key questions answered

* Evaluate the evolving regulatory landscape and the impact of pricing and reimbursement controls on market access in France
* Quantify the size and growth of the prescription pharmaceutical market in France, analyzing key therapy areas, brands and companies
* Assess drivers and resistors of generic and biosimilars uptake in France

[Studien Infos ausblenden]

Executive Summary
Introduction
Strategic scoping and focus
Key findings – healthcare drivers and resistors in France
France – Socio-demographic and economic analysis
France – Healthcare system and drug regulatory analysis
France – Prescription pharmaceutical sales analysis
France – Drug expiry analysis
France – Pharmaceutical Industry Infrastructure analysis
Related reports
Upcoming related reports
2. FRANCE – SOCIO-DEMOGRAPHIC AND ECONOMIC ANALYSIS
France – Key findings
Socio-demographic trends
Socioeconomic trends
France – Demographic trends
France’s population is increasing as the number of elderly people grows
The birth rate in France is higher than the rest of the EU
The number of elderly individuals and life expectancy are both increasing in France
France – Disease burden
A shift in diet is responsible for growing rates of heart disease, diabetes, and obesity
Cancer is responsible for high death rates in France
Alzheimer’s disease is associated with growing morbidity and mortality in France
France – Political climate
Corruption claims have shaken the public’s faith in France’s presidency
France – Economic climate
France’s relatively high productivity rates are being threatened by strike action against pension reforms
France’s budget deficit is projected to reach 8% of GDP in 2010
France – Business environment
The business environment in France is considered strong, but rigid labor laws keep unemployment high
Corporate income tax is relatively high in France
France welcomes foreign direct investment
French pharma industry is well developed but still has its downsides
The unemployment rate in France has continued to rise since the recession
3. FRANCE – HEALTHCARE SYSTEM AND DRUG REGULATORY ANALYSIS
France – Key findings
Healthcare expenditure
Healthcare insurance
Regulatory issues
Pricing and reimbursement issues
France – Healthcare expenditure
France has a higher than OECD average healthcare spend per capita, and a higher pharmaceutical spend
France – Insurance and healthcare system
France has a social security system provided by three main health insurance schemes
Primary care versus hospital care in France
France – Regulatory issues
Drug approval and regulatory processes in France
The AFSSAPS is the national drugs regulatory body in France
AFFSAPS has received some criticism for being too lax on conflicts of interest
Intellectual property – patents are valid for 20 years from date of application in France
Data exclusivity issues in France – the 8+2+1 rule
Drug counterfeiting in France – the country is taking measures to improve transparency of the supply chain
France – Pricing and reimbursement
France has employed a range of cost-cutting tools
Key pricing and reimbursement bodies in France
High pharmaceutical expenditure in France has led to an evolving pricing and reimbursement process
The prices of most medicines are controlled in France
Pricing issues – pricing and reimbursement processes in France are interconnected
Reimbursement issues in France – reimbursement is decided on by UNCAM
4. FRANCE – PRESCRIPTION PHARMACEUTICAL SALES ANALYSIS
France – Key findings
Pharmaceutical market size
Leading therapy areas
Leading pharmaceutical brands
Leading pharmaceutical companies
France – Pharmaceutical market size
France – Leading therapy areas
Central nervous system was the largest therapy area in terms of sales
Oncology drugs have shown the fastest growth rates
Gastroenterology drugs have shown the sharpest decline in growth rates
France – Leading pharmaceutical brands
Plavix is the top-selling pharmaceutical brand, although its position will be jeopardized due to intensifying generic competition
Lipitor will see a sharp decline in sales following the imminent patent expiry in 2011
Avastin’s impressive growth rates are set to continue in the future
France – Leading pharmaceutical companies
Sanofi-Aventis is the largest pharmaceutical company in France
Mylan is the largest generics company in France
The top 10 France-based pharmaceutical companies
5. FRANCE – DRUG EXPIRY ANALYSIS
France – Key findings
Generics market
Brand erosion post patent expiry
Biosimilars market
France – Generics market dynamics
France generics volume uptake
France generics value uptake
France generics market size
France – Generics drivers and resistors
Physicians are the key to increasing generic uptake in France
Proposed price cuts will damage generic players
Reference pricing increases competition from original brands…
…but changes to the reference pricing system could increase generic penetration significantly
The repertoire has driven generics uptake; however, physicians are impeding its wider usage
Dominance of branded generics limits uptake for smaller players
Pharmacists are increasingly using purchasing groups, since pharmacy chains are not permitted
Publicity campaigns are used to drive generic uptake patients, but brand loyalty is a significant barrier
Raids on generic companies and allegations of illegal activities hamper uptake
France – Key generics players
Mylan is a market leader in France
Teva to become a strong force in French generic sales
Opportunities for the generics industry
France – Small molecule brand erosion
Overview of drugs analyzed
Mean level of brand erosion in France
Brand erosion in the French retail and hospital setting
Brand erosion by therapy area in France
Brand erosion by drug formulation in France
France – Biosimilars market dynamics
Drivers and resistors to biosimilar uptake in France
Originators maintain prices in the face of biosimilar competition
Approved biosimilars
Biosimilar epoetin
Biosimilar filgrastim
Biosimilar somatropin
Key players in the French biosimilars market
Opportunities for the biosimilar industry
6. FRANCE – PHARMACEUTICAL INDUSTRY INFRASTRUCTURE ANALYSIS
France – Key findings
Pharmaceutical industry infrastructure overview
France – Pharmaceutical industry infrastructure overview
The manufacturing sector in France is increasingly focused on innovative biologics production
France is set to become an R&D hotspot
R&D and manufacturing strategies in France
France – Key company infrastructure
Sanofi-Aventis
Pfizer
Merck & Co.
Roche
Novartis
AstraZeneca
GlaxoSmithKline
Servier
Mylan
Johnson & Johnson
7. BIBLIOGRAPHY
France – Executive summary
Publications and online articles
Datamonitor reports and products
France – Socio-demographic and economic analysis
Publications and online articles
France – Healthcare systems and regulations
Publications and online articles
Datamonitor reports and products
France – Prescription pharmaceutical sales
Publications and online articles
Datamonitor reports and products
France – Drug expiry analysis
Publications and online articles
Datamonitor reports and products
France – Pharmaceutical industry infrastructure analysis
Publications and online articles
Datamonitor reports and products
APPENDIX
Exchange rates used in this report
Brand erosion – additional data and analysis
Brand erosion – methodology
Datamonitor prescription pharmaceutical definition and therapy area classification

[Inhaltsverzeichnis ausblenden]